 |
| What is Type 1 diabetes? | What is the AIDA study? | How to Join | Clinical Centers and Locations | Contact Us | Home |
Where do I go?
AIDA Participating Clinical Centers - Germany
Screening and regular visits can occur at any of our Participating Clinical Centers in Germany. For more information, contact:
Frankfurt:
Gesine Meyer
Prof.Dr. med.
gesine.meyer@kgu.de
Klinikum Johann Wolfgang Goethe-Universität
Schwerpunkt Endokrinologie-Diabetologie
Medizinische Klinik 1
Theodor-Stern-Kai 7
60590 Frankfurt
Germany
P: +49(0)69 6301 5647
F: +49(0)69 6301 7817
Maria Sandler
Study Coordinator
Maria.Sandler@kgu.de
Klinikum Johann Wolfgang Goethe-Universität
Schwerpunkt Endokrinologie-Diabetologie
Medizinische Klinik 1
Theodor-Stern-Kai 7
60590 Frankfurt
Germany
P: +49(0)69 6301 7818
F: +49(0)69 6301 4462
Ulm
Bernhard Boehm
Prof. Dr. med.
bernhard.boehm@uniklinik-ulm.deUniversitätsklinikum Ulm
Zentrum für Innere Medizin
Klinik für Innere Medizin I
Albert-Einstein-Allee 23
D-89081 UlmP: +49 (0)731 500 44504
F: +49 (0)731 500 44506Silke Rosinger
Dr. hum. biol.
Study Coordinator
silke.rosinger@uniklinik-ulm.deUniversitätsklinikum Ulm
Zentrum für Innere Medizin
Klinik für Innere Medizin I
Albert-Einstein-Allee 23
D-89081 UlmP: +49 (0)731 500 44515
F: +49 (0)731 500 44519
Munich
David Wiesenäcker
Dr. med.
David.Wiesenaecker@lrz.uni-muenchen.deInstitut für Diabetesforschung der
Forschergruppe Diabetes e.V.
am Helmholtz Zentrum
und Forschergruppe Diabetes der
Technischen Universität München
Kölner Platz 1
D-80804 MünchenP: +49 (0)89 3068 2917
F: +49 (0)89 3068 7509
Düsseldorf
Nanette Schloot
PD Dr. med.
nanette.schloot@web.deDeutsches Diabetes-Zentrum
Studienzentrum
Auf‘m Hennekamp 65
D-40225 DüsseldorfP: +49 (0)211 3382 209
F: +49 (0)211 3382 603
What is  |
The aim of the Anti-Interleukin-1 in Diabetes Action trial (AIDA) study is to test the feasibility, safety/tolerability and potential efficacy of anti-IL-1 therapy in maintaining or enhancing beta-cell function in people with new-onset Type 1 diabetes. The study employs a randomized, placebo-controlled, double-masked, parallel-group, multi-centre design. Participating clinical centres are located in 11 countries throughout Europe. |
Supported by: The active drug (Kineret®) and the non active “dummy” drug are provided by Amgen. Amgen does not provide funding for the conduct of the trial or to the researchers. The expenses of the trial are funded by grants from Juvenile Diabetes Foundation International, New York, USA, the world’s largest private diabetes fund. Funding also provided by Oresund Diabetes Academy and Steno Diabetes Center, Denmark. |
| Site Map | Contact Us | AIDA Locations | Accessibility | Contact the Web Master | AIDA Member Web Site | |
